Alto Neuroscience Inc. (NYSE: ANRO) presented data from a Phase 2a trial of ALTO-207 in patients with major depressive disorder ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE